Last updated on September 2018

A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours


Brief description of study

This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.

Clinical Study Identifier: NCT03009214

Contact Investigators or Research Sites near you

Start Over

Marta Gil, MD PhD

Institut Catal d'Oncologia, Hospital Duran i Reynals
L'Hospitalet-Barcelona, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.